MetaCap

CervoMed (CRVO) vs Incannex Healthcare (IXHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Incannex Healthcare (IXHL) has outperformed CervoMed (CRVO) over the past year, losing 80.3% versus a loss of 83.6%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $22.1 million), about 1.1 times the size, while CervoMed is growing revenue faster (-58.9% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRVO-83.56%IXHL-80.32%
+59%-16%-92%
Nov 21, 20251 yearNov 20, 2026
CRVO-92.21%IXHL-99.88%
+41%-33%-107%
Feb 28, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRVO versus IXHL key metrics
MetricCRVOIXHL
Share price$1.46$1.86
Market cap$22.09M$23.34M
1-day change+9.77%+6.90%
YTD return-81.52%-82.68%
1-year return-83.56%-80.32%
5-year return-95.01%—
EPS (TTM)$-2.65$-1.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.01M$0
Revenue growth (YoY)-58.86%-100.00%
Net income (latest FY)$-26.97M$-19.30M
Operating margin-706.22%—
Net margin-673.06%—
52-week high$10.00$14.91
52-week low$1.27$1.61
Distance from 52-week high-85.40%-87.53%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+954.79%+904.30%
Average volume489.10K91.61K
Shares outstanding15.13M12.55M
Employees1512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CervoMed grew revenue faster in its latest fiscal year (-58.86% vs -100.00%).

About CervoMed

CRVO stock →

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Incannex Healthcare

IXHL stock →

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

CRVO vs IXHL FAQ

Which is bigger, CervoMed or Incannex Healthcare?

Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $22.09M for CervoMed (CRVO).

Which stock has performed better over the past year, CRVO or IXHL?

IXHL returned -80.32% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.

Are CervoMed and Incannex Healthcare in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons